Skip to content

Personalis

US · PSNL #2890 by market cap Listed 2019
14.27 -0.45 -3.06%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 8.01 Expensive vs history 100th percentile
5-year average 2.05 · #32 of 41 in Diagnostics & Research
P/E ratio -13.54 Cheap vs history 6th percentile
5-year average -4.41 · forward -17.44
P/S ratio 21.08 Expensive vs history 93rd percentile
5-year average 5.86 · forward 16.31 · #39 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Personalis (PSNL) 1.55B -12.30 7.27 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value23.67 Economic moatNone UncertaintyVery High

Trading 65.9% below Morningstar's fair value estimate.

Fair value

Personalis Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 34% discount to our quantitative fair value estimate of $23.67 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 9.0, which lies in the top 45% globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. We believe this is a sign that shares could be undervalued.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's gross margin of 18.3%, a core component of profitability, lies in the bottom 30% globally. This suggests that competition is intense and profit generation could prove difficult. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Personalis discussion 0 comments

Add a comment